Abstract:

The main objective of this study was to assess how Knowledge, behavior and perceptions affect Cervical Cancer screening and the control of HIV/ HPV Co-infection among patients with cervical cancer in Kenya. The following specific objectives guided the study; to weigh the knowledge, behavior, and perceptions on the understanding of the absorption of Cervical Cancer Screening and prevention strategies among women in Kenya. This was a cross-sectional, descriptive and quantitative comparative study of cervical neoplasia screening and control strategies among women attending Kenyatta National Hospital and Coast Provincial General Hospitals in Kenya. The study was conducted at the Coastal region of Kenya particularly Mombasa County and all parts of Nairobi County over a twelve-month period at the Coast Provincial General Hospital (CPGH) and Kenyatta National Hospital respectively. The target population for this work involved all female respondents who had tested positive for HIV and Cervical Cancer and have the results or they need further screening. Convenience sampling technique was used because of time constraints. Random sampling was used to identify participants. The study concludes that knowledge, behavior, and perceptions on absorption of Cervical Cancer Screening and prevention by women depend on initiatives that have been put in place to motivate and educate women on issues related to cancer screening. The study recommends that the need for community understanding of cervical cancer and the causal relationship between HPV and cervical cancer is usually poor, giving priority to continuing education on the significance of HPV prevention and periodic cervical Cancer screening.

References:

[1].   Adamson P.C, Huchko M.J, Moss A.M, Kinkel H.F, Medina-Marino A. (2015). Acceptability and accuracy of cervical cancer screening using a self-collected tampon for HPV messenger-RNA testing among HIV-infected women in South Africa. PLoS One.; 10(9): e0137299.

[2].   Addison, A., Dagin, A., Tadela, E., Addison, A., Mussie, A. and Filmon, K. (2015). CD4 Cell counts trends after commencement of antiretroviral therapy among HIV infected patients in Tigray, Northern Ethiopia. A Retrospective Cross-Sectional Study. PLos ONE, 1093) e0122583 http://doi.org/10.1371/journal.pone.0122583

[3].   Adler DH, Wallace M, Bennie T, et al. (2014). Cervical dysplasia and high-risk human papillomavirus infections among HIV-infected and HIV-uninfected adolescent females in South Africa. Infect Dis Obstet Gynecol. 2014; 2014:498048.

[4].   Adler D.H, Wallace M, Bennie T, et al. (2014). Cervical dysplasia and high-risk human papillomavirus infections among HIV-infected and HIV-uninfected adolescent females in South Africa. Infect Dis Obstet Gynecol; 2014:498048.

[5].   Africa: an association between highly prevalent infectious diseases (2010). A systematic review and meta-analysis. Int J Infect Dis 14(12): e1024–31. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20870439

[6].   Anderson J, Wysong M, Estep D, et al. (2015). Evaluation of cervical cancer screening programs in Côte d’Ivoire, Guyanasocio-demographicand Tanzania: effect of HIV status. PLoS One. 2015; 10(9): e0139242.

[7].   Arbyn M, Verdoot F, Snijders PJ, et al. (2014). Accuracy of human papil­lomavirus testing on self-collected versus clinician-collected samples: a meta-analysis. Lancet Oncol. 2014; 15(2):172–183.

[8].   Ault, K.A. (2007) Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. The Lancet; 369: 9576, 1861-1868.

[9].   Bayu H, Berhe Y, Mulat A, Alemu A. (2015). Cervical cancer screening service uptake and associated factors among age eligible women in Mekelle Zone, Northern Ethiopia, A community-based study using health belief model. PLoS One; 11(3): e0149908.

[10].  Bendacid, E., Philip, G., Ammie, T., Douglas, K. O. and Andrew, Z. (2011). Cost effectiveness of antiretroviral regimens in the World Health Organization. Treatment Guidelines: A South African analysis. Journal of Acquired Immunodeficiency Syndrome 25: 211-220.

[11].  Between cervical dysplasia and human papillomavirus in HIV seropositive women from Johannesburg South Africa. Cancer Causes Control. 2010; 21(3):433–43.

[12].  Bosch F.X, Broker T.R, Forman D, et al. (2013). Comprehensive control of human papillomavirus infections and related diseases.

[13].  Brown DR, Shew ML, Qadadri B, et al. (2005). A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. The Journal of Infectious Diseases; 191 (2):182–192.

[14].  Bukirwa A, Mutyoba JN, Mukasa B.N et al. (2015). Motivations and barriers to cervical cancer screening among HIV infected women in HIV care: a qualitative study. BMC Womens Health.15:82.

[15].  Cancer IIAfRo. GLOBOCAN (2012): Estimated cancer incidence, mortality and prevalence worldwide in 2012. In: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx, editor.

[16].  Cattani P, Zannoni GF, Ricci C, et al. (2009). Clinical performance of human papillomavirus E6 and E7 mRNA testing for high-grade lesions of the cervix. J Clin Microbiol; 4 7(12):3895–3901.

[17].  Christine Danel, Delphine Gabillard, Jerome Le Carro, Xavier Anglaret1, Raoul Moh, Serge Eholie, Hervé Ménan, Anani Badje, Gerard Kouame JBN. Early ART and IPT in HIV-Infected African Adults with High CD4 Count (Temprano Trial) (2015). Conference on Retroviruses and Opportunistic Infections (CROI) [Internet]. Seattle, Washington, USA; Available from: http://www.croiconference.org/sessions/early-art-andipt- hiv-infected-african-adults-high-cd4-count-temprano-trial.

[18].  Chung MH, McKenzie K, De Vuyst H, et al. (2013). Comparing papanicolau smear, visual inspection with acetic acid and human papillomavirus cervical cancer screening methods among HIV-positive women by immune status and antiretroviral therapy. AIDS ;27 (18): 2909–2919.

[19].  Clifford G.M, Franceschi S, Keiser O, et al. (2016). Immunodeficiency and the risk of cervical intraepithelial neoplasia 2/3 and cervical cancer: a nested case-control study in the Swiss HIV cohort study. Int J Cancer; 138 (7):1732–1740.

[20].  Cronjé H.S (2004). Screening for cervical cancer in developing countries. Int J Gynecol Obstet; 84(2):101–108.

[21].  DeGregorio GA, Bradford LS, Manga S, et al. (2016). Prevalence, predictors and same day treatment of positive VIA enhanced by digital cervicography and histopathology results in a cervical cancer prevention program. PLoS One. 2016; 11(6): e0157319.

[22].  Denny L, Anorlu R. (2012). Cervical cancer in Africa. Cancer Epidemiol Biomarkers Prev; 21(9):1434–1438.

[23].  Denny L, de Sanjose S, Mutebi M. (2016). Interventions to close the divide for women with breast and cervical cancer between low-income and middle-income countries and high-income countries. Lancet.

[24].  Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBO­CAN (2008). Cancer Incidence and Mortality Worldwide: IARC Cancer­ Base No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. Available from:  https://www.iarc.fr/en/media-centre/iarcnews/2010/globocan2008.php. Accessed January 13, 2017.

[25].  Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN (2012). Can­cer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Inter­net]. Available from:  http://globocan.iarc.fr. Accessed July 22, 2016.

[26].  Fink MJ, Frucher RG, Maiman M, et al. (1994). The adequacy of cytology and colposcopy in diagnosing cervical neoplasia in HIV-seropositive women. Gynecol Oncol. 55 (1):133–137.

[27].  Firnhaber C, Mao L, Levin S, et al. (2015). Evaluation of a cervicography-based program to ensure quality of visual inspection of the cervix in HIV-infected women in Johannesburg, South Africa. J Low Gen Tract Dis; 19 (1):7–11.

[28].  Firnhaber C, Mayisela N, Mao L. (2013). Validation of cervical cancer screening methods in HIV positive women from Johannesburg South Africa. PLoS One. 2013; 8 (1): e53494.

[29].  Fletcher F.E, Buchberg M, Schover L.R. (2014). Perceptions of barriers and facilitators to cervical cancer screening among low-income, HIV-infected women from an integrated HIV clinic. AIDS Care; 26(10): 1229–1235.

[30].  Frazier EL, Sutton MY, Tie Y, McNaghten AD, Blair JM, Skarbinski J. (2016). Screening for cervical cancer and sexually transmitted diseases among HIV-infected women. J Womens Health (Larchmt). 2016; 25(2): 124–132.

[31].  Gakidou E, Nordhagen S, Obermeyer Z. (2008). Coverage of cervical cancer screening in 57 countries: low average levels and large inequalities. PLoS Med 5(6): e132.

[32].   Ho GY, Kadish AS, Burk RD, et al. (1998). HPV 16 and cigarette smoking as risk factors for high-grade cervical intra-epithelial neoplasia. International Journal of Cancer; 78:281-285.

[33].  Hogewoning C.J, Bleeker M.C, van den Brule A.J, et al. (2003). Condom use promotes regression of cervical intraepithelial neoplasia and clearance of human papillomavirus: a randomized clinical trial. International Journal of Cancer. 2003; 107(5):811–816.

[34].  Huchko MJ, Sneden J, Leslie HH, et al. (2014). A comparison of two visual inspection methods for cervical cancer screening among HIV-infected women in Kenya. Bull World Health Organ;92(3):195–203.

[35].  Huchko MJ, Sneden J, Sawaya G, et al. (2015). Accuracy of visual inspection with acetic acid to detect cervical cancer precursors among HIV-infected women in Kenya. Int J Cancer;136(2):392–398.

[36].  Jemal A, Bray F, Forman D, et al. (2012). Cancer burden in Africa and opportunities for prevention. Cancer; 118 (18):4372-84.

[37].  Jemal A, Center MM, DeSanctis C, Ward EM. (2010). Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev; 19 (8):1893–1907.

[38].  Keller M.J (2015). Screening for human papillomavirus-associated cervi­cal disease in HIV-infected women. Top Antivir Med; 23(4): 142–145.